Semaglutide vs Tirzepatide: Which Weight Loss Peptide Is Better?

Semaglutide and tirzepatide are the two most effective weight loss peptides with clinical approval — and the two most commonly compared. Both are once-weekly injections that suppress appetite and improve metabolic health, but they work through different mechanisms and produce different results. This comparison covers everything you need to decide between them in the Thai market.

Semaglutide is a single-target GLP-1 receptor agonist. It mimics one gut hormone (GLP-1) to suppress appetite, slow gastric emptying, and improve insulin response. It has been the gold standard for peptide-based weight loss since 2021.

Tirzepatide is a dual-target GLP-1/GIP receptor agonist — a 'twincretin' that activates two incretin pathways simultaneously. The added GIP receptor activation appears to enhance insulin secretion, modulate fat metabolism, and may contribute to better GI tolerability. The dual mechanism is why tirzepatide produces significantly more weight loss than semaglutide.

This is where tirzepatide clearly wins. In clinical trials:

• Semaglutide produced average weight loss of ~14.9% of body weight at the 2.4 mg dose over 68 weeks
• Tirzepatide produced average weight loss of ~20.9% at the 15 mg dose over 72 weeks

The SURMOUNT-5 head-to-head trial confirmed tirzepatide produces roughly 47% more weight loss than semaglutide when compared directly.

However, individual responses vary significantly. Some people respond better to semaglutide, and ~15% weight loss is still a transformative result for most people.

Both produce GI side effects — nausea, diarrhea, constipation, vomiting — primarily during dose escalation. However, tirzepatide may have a somewhat better tolerability profile:

• Nausea rates: ~44% (semaglutide at highest dose) vs ~31% (tirzepatide at highest dose)
• Treatment discontinuation due to side effects: ~7% (semaglutide) vs ~6.2% (tirzepatide)

The GIP component in tirzepatide may have antiemetic properties that partially counteract the GLP-1-induced nausea. Many users switching from semaglutide to tirzepatide report improved GI tolerance.

Both carry the same class warnings: pancreatitis risk, gallbladder issues, thyroid C-cell concerns from rodent studies.

Semaglutide is far more widely available in Thailand. It is Thai FDA-approved, stocked at most hospitals, many pharmacies, and available from all major peptide vendors. Both brand-name pens and research-grade formulations are accessible. It is the easier and cheaper option to source.

Tirzepatide has more limited availability. Branded pharmaceutical pens are available through select Bangkok clinics. Research-grade tirzepatide is accessible through peptide vendors with domestic shipping. Availability is expanding but remains less widespread than semaglutide.

Choose semaglutide if: - You are new to GLP-1 agonists and want to start with the most established option - Budget is a consideration — semaglutide is more affordable and widely available in Thailand - You prefer an oral option (semaglutide has a daily tablet form) - You want the longest safety track record

Choose tirzepatide if: - Maximum weight loss is your priority - You tried semaglutide and plateaued or want greater results - You experienced significant nausea on semaglutide (tirzepatide may be better tolerated) - You do not mind limited Thai availability and potentially higher cost

The practical approach for many people in Thailand: Start with semaglutide (more accessible, more affordable, proven effective). If you plateau or want more aggressive results after 3-6 months, consider switching to tirzepatide.